SPRB revenueQ4 2025$0
- Quarter YoY
- -100.0%
- FY YoY
- -100.0%
SPRB revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), down 100.0% from a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
Spruce Biosciences Inc. (SPRB) financials
For fiscal 2025 (ended Dec 31, 2025), Spruce Biosciences Inc. reported $0 of revenue and -$38.97M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$38.97M
- EPS, diluted, FY2025
- -$50.83
- Cash
- $96.30M
- Total debt
- $7.09M
- Market cap
- $133.8M
FY2022FY2025
FY2019FY2025
FY2019FY2024
SPRB revenue and earnings growth
SPRB net incomeQ2 2026-$16.23M
SPRB net income was -$16.23M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.07M a year earlier. For the full fiscal 2025 it was -$38.97M, compared with -$53.04M in fiscal 2024.
SPRB EPSQ2 2026-$6.68
SPRB diluted EPS was -$6.68 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$50.83, compared with -$96.40 in fiscal 2024.
SPRB free cash flowQ2 2026-$22.25M
SPRB free cash flow was -$22.25M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.83M a year earlier. For the full fiscal 2024 it was -$55.96M, compared with -$33.28M in fiscal 2023.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $4.91M | $10.09M | $0 | - | - | - |
| Research and development | $19.52M | $46.42M | $49.43M | $35.20M | $30.70M | $23.85M | $10.82M |
| Selling, general and admin | $16.99M | $14.64M | $12.65M | $12.09M | $11.37M | $5.56M | $2.29M |
| Operating income | -$36.51M | -$56.15M | -$51.99M | -$47.28M | -$42.07M | -$29.42M | -$13.11M |
| Interest expense | $90.0K | $307.0K | $483.0K | $420.0K | $345.0K | $323.0K | $65.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$38.97M | -$53.04M | -$47.92M | -$46.18M | -$42.29M | -$29.54M | -$13.09M |
| EPS, basic | -$50.83 | -$96.40 | -$93.00 | -$147.00 | -$135.75 | -$369.75 | -$1284.00 |
| EPS, diluted | -$50.83 | -$96.40 | -$93.00 | -$147.00 | -$135.75 | -$369.75 | -$1284.00 |
| Diluted shares | 766,598 | 550,146 | 513,469.6 | 313,694.88 | 311,485.547 | 79,882.84 | 10,192.107 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.91M | $38.79M | $96.37M | $24.73M | $42.96M | $157.37M | $3.92M |
| Short-term investments | - | - | $0 | $54.59M | $46.22M | - | - |
| Receivables | - | - | - | $0 | - | - | - |
| Current assets | $52.11M | $44.21M | $102.18M | $83.61M | $91.89M | $160.40M | $4.65M |
| Total assets | $53.02M | $45.21M | $103.95M | $85.65M | $126.49M | $162.88M | $4.69M |
| Current liabilities | $10.09M | $15.25M | $24.46M | $12.45M | $8.87M | $9.76M | $4.30M |
| Short-term debt | $0 | $1.62M | $1.62M | $1.62M | $0 | $2.55M | $1.25M |
| Long-term debt | $0 | $124.0K | $1.72M | $3.29M | $4.88M | $1.92M | $3.19M |
| Total debt | $0 | $1.75M | $3.34M | $4.92M | $4.88M | $4.48M | $4.45M |
| Total liabilities | $10.51M | $16.39M | $27.44M | $17.16M | $15.12M | $13.46M | $7.52M |
| Shareholders' equity | $42.52M | $28.82M | $76.51M | $68.49M | $111.37M | $149.43M | -$30.64M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.33M | -$55.96M | -$33.27M | -$41.68M | -$35.88M | -$27.52M | -$12.62M |
| Capital expenditures | - | $0 | $7.0K | $8.0K | $93.0K | $74.0K | $4.0K |
| Free cash flow | - | -$55.96M | -$33.28M | -$41.69M | -$35.97M | -$27.59M | -$12.62M |
| Investing cash flow | - | $0 | $55.78M | $23.69M | -$79.17M | -$74.0K | -$4.0K |
| Financing cash flow | $43.48M | -$1.62M | $49.14M | -$241.0K | $643.0K | $181.03M | $12.43M |
| Stock-based compensation | $2.57M | $5.35M | $4.62M | $3.63M | $3.96M | $755.0K | $196.0K |
| Depreciation and amortization | $21.0K | $46.0K | $70.0K | $74.0K | $68.0K | $36.0K | $12.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -51.3% | - | - | - | - | - |
| Operating margin | - | -1143.4% | -515.3% | - | - | - | - |
| Net margin | - | -1079.9% | -475.0% | - | - | - | - |
| Free cash flow margin | - | -1139.6% | -329.9% | - | - | - | - |
| Return on equity | -91.7% | -184.0% | -62.6% | -67.4% | -38.0% | -19.8% | - |
| Return on assets | -73.5% | -117.3% | -46.1% | -53.9% | -33.4% | -18.1% | -278.9% |
| Current ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 | 16.43 | 1.08 |
| Debt to equity | 0.00 | 0.06 | 0.04 | 0.07 | 0.04 | 0.03 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | $0 | $697.0K | $602.0K | $1.61M | $2.00M | $2.89M | $3.07M |
| Research and development | $12.16M | $7.58M | $4.10M | $5.01M | -$430.0K | $10.84M | $21.46M | $6.55M | $8.09M | $10.32M | $11.10M | $13.49M |
| Selling, general and admin | $4.35M | $4.41M | $7.00M | $3.22M | $3.12M | $3.65M | $3.31M | $3.46M | $3.56M | $4.32M | $2.95M | $3.24M |
| Operating income | -$16.51M | -$11.99M | -$11.10M | -$8.23M | -$2.69M | -$14.49M | -$24.07M | -$9.41M | -$10.04M | -$12.63M | -$11.16M | -$13.66M |
| Interest expense | $1.10M | $674.0K | $6.0K | $19.0K | $29.0K | $36.0K | $56.0K | $71.0K | $83.0K | $97.0K | $106.0K | $119.0K |
| Net income | -$16.23M | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | -$23.56M | -$8.67M | -$9.18M | -$11.63M | -$9.95M | -$12.35M |
| EPS, basic | -$6.68 | -$8.94 | - | -$14.58 | -$3.50 | -$23.95 | -$42.92 | -$15.75 | -$16.73 | -$21.00 | - | -$22.50 |
| EPS, diluted | -$6.68 | -$8.94 | - | -$14.58 | -$3.50 | -$23.95 | -$42.92 | -$15.75 | -$16.73 | -$21.00 | - | -$22.50 |
| Diluted shares | 2.4M | 1.4M | - | 563,066 | 591,137 | 586,142 | - | 550,645 | 548,789 | 547,949.747 | - | 542,809.227 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $96.30M | $54.08M | $48.91M | $10.67M | $16.39M | $25.61M | $38.79M | $60.05M | $69.68M | $81.15M | $96.37M | $98.80M |
| Short-term investments | - | - | - | - | - | - | - | - | - | - | $0 | $9.23M |
| Current assets | $101.15M | $55.03M | $52.11M | $14.52M | $20.95M | $30.58M | $44.21M | $63.57M | $73.91M | $85.86M | $102.18M | $111.14M |
| Total assets | $102.85M | $56.17M | $53.02M | $15.31M | $21.82M | $31.65M | $45.21M | $65.10M | $75.52M | $87.54M | $103.95M | $112.98M |
| Current liabilities | $10.96M | $11.78M | $10.09M | $9.43M | $8.06M | $15.67M | $15.25M | $11.86M | $14.29M | $18.39M | $24.46M | $24.19M |
| Short-term debt | $2.50M | $1.00M | $0 | $539.0K | $943.0K | $1.34M | $1.62M | $1.62M | $1.62M | $1.62M | $1.62M | $1.62M |
| Long-term debt | $4.59M | $5.46M | $0 | $0 | $0 | $0 | $124.0K | $524.0K | $923.0K | $1.32M | $1.72M | $2.11M |
| Total debt | $7.09M | $6.46M | $0 | $539.0K | $943.0K | $1.34M | $1.75M | $2.15M | $2.54M | $2.94M | $3.34M | $3.73M |
| Total liabilities | $19.12M | $21.52M | $10.51M | $9.93M | $8.64M | $16.32M | $16.39M | $13.46M | $16.35M | $20.91M | $27.44M | $27.60M |
| Shareholders' equity | $83.73M | $34.65M | $42.52M | $5.39M | $13.18M | $15.32M | $28.82M | $51.64M | $59.17M | $66.62M | $76.51M | $85.38M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.12M | -$8.73M | -$6.46M | -$5.32M | -$8.83M | -$12.73M | -$20.68M | -$9.22M | -$11.11M | -$14.96M | -$11.21M | -$12.27M |
| Capital expenditures | $135.0K | $10.0K | - | - | $0 | $0 | $0 | - | - | - | $0 | $7.0K |
| Free cash flow | -$22.25M | -$8.74M | - | - | -$8.83M | -$12.73M | -$20.68M | - | - | - | -$11.21M | -$12.28M |
| Investing cash flow | -$135.0K | -$10.0K | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $9.30M | $13.99M |
| Financing cash flow | $64.47M | $13.92M | $44.69M | -$402.0K | -$400.0K | -$411.0K | -$625.0K | -$405.0K | -$365.0K | -$227.0K | -$552.0K | -$405.0K |
| Stock-based compensation | $871.0K | $689.0K | $1.69M | $415.0K | -$77.0K | $544.0K | $961.0K | $1.14M | $1.69M | $1.56M | $1.22M | $1.12M |
| Depreciation and amortization | $631.0K | $252.0K | $5.0K | $3.0K | $7.0K | $6.0K | $9.0K | $10.0K | $12.0K | $15.0K | $16.0K | $17.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | -100.0% | -100.0% | -100.0% | -75.9% | -80.4% | -25.6% | 1.9% | - | - |
| Operating margin | - | - | - | - | - | - | -3453.9% | -1562.8% | -623.4% | -631.0% | -386.7% | -444.5% |
| Net margin | - | - | - | - | - | - | -3380.1% | -1440.4% | -570.2% | -580.7% | -344.6% | -402.0% |
| Free cash flow margin | - | - | - | - | - | - | -2966.6% | - | - | - | -388.3% | -399.5% |
| Current ratio | 9.23 | 4.67 | 5.17 | 1.54 | 2.60 | 1.95 | 2.90 | 5.36 | 5.17 | 4.67 | 4.18 | 4.59 |
| Debt to equity | 0.08 | 0.19 | 0.00 | 0.10 | 0.07 | 0.09 | 0.06 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Source: XBRL data Spruce Biosciences Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-75, first reported Aug 14, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SPRB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SPRB | $0 | -100.0% | -$38.97M | - | $133.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
SPRB FAQ
7 questionsWhat is SPRB revenue?
Spruce Biosciences Inc. (SPRB) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is SPRB profitable?
No. Spruce Biosciences Inc. reported a net loss of $38.97M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SPRB have?
Spruce Biosciences Inc. reported $96.30M in cash and cash equivalents and $7.09M of debt on its most recent balance sheet in SEC filings.How fast is SPRB revenue growing?
Spruce Biosciences Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is SPRB earnings per share?
Diluted earnings per share were -$50.83 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did SPRB last report financial results?
The latest statements here come from Spruce Biosciences Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this SPRB financial data come from?
Quantisnow builds these statements from the structured XBRL data Spruce Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.